{
    "relation": [
        [
            "Feature key",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti",
            "Describes natural variant(s) of the protein sequence.More...Natural varianti"
        ],
        [
            "Position(s)",
            "19 \u2013 19",
            "24 \u2013 24",
            "24 \u2013 24",
            "32 \u2013 32",
            "35 \u2013 35",
            "35 \u2013 35",
            "35 \u2013 35",
            "48 \u2013 48",
            "50 \u2013 50",
            "53 \u2013 53",
            "59 \u2013 59",
            "62 \u2013 62",
            "67 \u2013 67",
            "68 \u2013 68",
            "71 \u2013 71",
            "74 \u2013 74",
            "77 \u2013 77",
            "80 \u2013 80",
            "81 \u2013 81",
            "84 \u2013 84",
            "87 \u2013 87",
            "87 \u2013 87",
            "89 \u2013 89",
            "89 \u2013 89",
            "94 \u2013 94",
            "97 \u2013 97",
            "98 \u2013 98",
            "98 \u2013 98",
            "99 \u2013 99",
            "100 \u2013 100",
            "101 \u2013 101",
            "107 \u2013 107",
            "112 \u2013 112",
            "117 \u2013 117",
            "118 \u2013 118",
            "122 \u2013 122",
            "126 \u2013 126"
        ],
        [
            "Length",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1"
        ],
        [
            "Description",
            "A \u2192 ATA in CMM2; loss of CDK4 binding.",
            "R \u2192 C in CMM2.",
            "R \u2192 P in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.31 \"Germline mutations of the CDKN2 gene in UK melanoma families.\" Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N.K., Frischauf A.-M., Bataille V., Peters G., Cuzick J., Selby P., Bishop D.T., Bishop J.N. Hum. Mol. Genet. 6:2061-2067(1997) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-24; ILE-53 AND THR-118, VARIANT THR-148.",
            "L \u2192 P in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.27 \"Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.\" Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G., Dracopoli N.C., Hayward N.K., Fountain J.W. Hum. Mol. Genet. 4:1845-1852(1995) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, VARIANT THR-148.",
            "G \u2192 A in CMM2; also found in a biliary tract tumor and a patient with uveal melanoma; partial loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.27 \"Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.\" Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G., Dracopoli N.C., Hayward N.K., Fountain J.W. Hum. Mol. Genet. 4:1845-1852(1995) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, VARIANT THR-148.",
            "G \u2192 E in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.27 \"Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.\" Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G., Dracopoli N.C., Hayward N.K., Fountain J.W. Hum. Mol. Genet. 4:1845-1852(1995) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, VARIANT THR-148.",
            "G \u2192 V in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "P \u2192 L in CMM2; also found in head and neck tumor; somatic mutation. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.33 \"Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas.\" Gretarsdottir S., Olafsdottir G.H., Borg A. Hum. Mutat. 12:212-212(1998) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 LEU-48; ASP-89 AND MET-117, VARIANT PANCREAS CARCINOMA VAL-57, VARIANT THR-148.",
            "Q \u2192 R in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.27 \"Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.\" Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G., Dracopoli N.C., Hayward N.K., Fountain J.W. Hum. Mol. Genet. 4:1845-1852(1995) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, VARIANT THR-148.",
            "M \u2192 I in CMM2. 3 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.27 \"Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds.\" Walker G.J., Hussussian C.J., Flores J.F., Glendening J.M., Haluska F.G., Dracopoli N.C., Hayward N.K., Fountain J.W. Hum. Mol. Genet. 4:1845-1852(1995) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-32; ALA-35; GLU-35; ARG-50 AND ILE-53, VARIANT THR-148. Ref.30 \"Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.\" Fitzgerald M.G., Harkin D.P., Silva-Arrieta S., Macdonald D.J., Lucchina L.C., Unsal H., O'Neill E., Koh J., Finkelstein D.M., Isselbacher K.J., Sober A.J., Haber D.A. Proc. Natl. Acad. Sci. U.S.A. 93:8541-8545(1996) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 ILE-53 AND CYS-107, VARIANTS VAL-68; THR-85 AND THR-148. Ref.31 \"Germline mutations of the CDKN2 gene in UK melanoma families.\" Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N.K., Frischauf A.-M., Bataille V., Peters G., Cuzick J., Selby P., Bishop D.T., Bishop J.N. Hum. Mol. Genet. 6:2061-2067(1997) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-24; ILE-53 AND THR-118, VARIANT THR-148.",
            "V \u2192 G in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.38 \"CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.\" Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M., Puig L., Sanchez-Conejo J., Estivill X., Castel T. J. Med. Genet. 36:490-493(1999) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 GLY-59; TYR-84; TRP-87 AND TRP-101.",
            "L \u2192 P in CMM2.",
            "G \u2192 R in CMM2; partial loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "A \u2192 L in CMM2; requires 2 nucleotide substitutions.",
            "N \u2192 K in CMM2.",
            "D \u2192 Y in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "T \u2192 P in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "R \u2192 P in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "P \u2192 T in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "D \u2192 Y in CMM2; also found in a lung tumor and a prostate tumor. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.38 \"CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.\" Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M., Puig L., Sanchez-Conejo J., Estivill X., Castel T. J. Med. Genet. 36:490-493(1999) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 GLY-59; TYR-84; TRP-87 AND TRP-101. Corresponds to variant rs11552822 [ dbSNP | Ensembl ].",
            "R \u2192 P in CMM2; impairs the function. 2 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.24 \"Germline p16 mutations in familial melanoma.\" Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A.T., Ally D.S., Sheahan M.D., Clark W.H. Jr., Tucker M.A., Dracopoli N.C. Nat. Genet. 8:15-21(1994) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-87; TRP-101 AND ASP-126, VARIANTS THR-49; SER-71 AND THR-148. Ref.28 \"Mutations associated with familial melanoma impair p16INK4 function.\" Ranade K., Hussussian C.J., Sikorski R.S., Varmus H.E., Goldstein A.M., Tucker M.A., Serrano M., Hannon G.J., Beach D., Dracopoli N.C. Nat. Genet. 10:114-116(1995) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS THR-49; SER-71; LEU-81; PRO-87; TRP-101; ASP-126 AND THR-148.",
            "R \u2192 W in CMM2; partial loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.38 \"CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.\" Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M., Puig L., Sanchez-Conejo J., Estivill X., Castel T. J. Med. Genet. 36:490-493(1999) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 GLY-59; TYR-84; TRP-87 AND TRP-101.",
            "G \u2192 D in CMM2; somatic mutation. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.33 \"Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas.\" Gretarsdottir S., Olafsdottir G.H., Borg A. Hum. Mutat. 12:212-212(1998) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 LEU-48; ASP-89 AND MET-117, VARIANT PANCREAS CARCINOMA VAL-57, VARIANT THR-148.",
            "G \u2192 S in CMM2.",
            "L \u2192 Q in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.40 \"A novel L94Q mutation in the CDKN2A gene in a melanoma kindred.\" Avbelj M., Hocevar M., Trebusak-Podkrajsek K., Krzisnik C., Battelino T. Melanoma Res. 13:567-570(2003) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CMM2 GLN-94.",
            "L \u2192 R in CMM2; loss of CDK4 binding. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.41 \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Kannengiesser C., Brookes S., del Arroyo A.G., Pham D., Bombled J., Barrois M., Mauffret O., Avril M.F., Chompret A., Lenoir G.M., Sarasin A., Peters G., Bressac-de Paillerets B. Hum. Mutat. 30:564-574(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS.",
            "H \u2192 P in CMM2.",
            "H \u2192 Q in CMM2.",
            "R \u2192 P in CMM2; loss of CDK4 binding.",
            "A \u2192 L in CMM2; requires 2 nucleotide substitutions.",
            "G \u2192 W in CMM2 and FAMMMPC; impairs the function. 3 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.24 \"Germline p16 mutations in familial melanoma.\" Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A.T., Ally D.S., Sheahan M.D., Clark W.H. Jr., Tucker M.A., Dracopoli N.C. Nat. Genet. 8:15-21(1994) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-87; TRP-101 AND ASP-126, VARIANTS THR-49; SER-71 AND THR-148. Ref.28 \"Mutations associated with familial melanoma impair p16INK4 function.\" Ranade K., Hussussian C.J., Sikorski R.S., Varmus H.E., Goldstein A.M., Tucker M.A., Serrano M., Hannon G.J., Beach D., Dracopoli N.C. Nat. Genet. 10:114-116(1995) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS THR-49; SER-71; LEU-81; PRO-87; TRP-101; ASP-126 AND THR-148. Ref.38 \"CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.\" Ruiz A., Puig S., Malvehy J., Lazaro C., Lynch M., Gimenez-Arnau A.M., Puig L., Sanchez-Conejo J., Estivill X., Castel T. J. Med. Genet. 36:490-493(1999) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 GLY-59; TYR-84; TRP-87 AND TRP-101.",
            "R \u2192 C in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.30 \"Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.\" Fitzgerald M.G., Harkin D.P., Silva-Arrieta S., Macdonald D.J., Lucchina L.C., Unsal H., O'Neill E., Koh J., Finkelstein D.M., Isselbacher K.J., Sober A.J., Haber D.A. Proc. Natl. Acad. Sci. U.S.A. 93:8541-8545(1996) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 ILE-53 AND CYS-107, VARIANTS VAL-68; THR-85 AND THR-148.",
            "R \u2192 RR in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.29 \"Novel germline p16 mutation in familial malignant melanoma in southern Sweden.\" Borg A., Johannsson U., Johannsson O., Haakansson S., Westerdahl J., Maasbaeck A., Olsson H., Ingvar C. Cancer Res. 56:2497-2500(1996) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CMM2 ARG-112 INS, VARIANT THR-148.",
            "L \u2192 M in CMM2; somatic mutation. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.33 \"Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas.\" Gretarsdottir S., Olafsdottir G.H., Borg A. Hum. Mutat. 12:212-212(1998) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 LEU-48; ASP-89 AND MET-117, VARIANT PANCREAS CARCINOMA VAL-57, VARIANT THR-148.",
            "A \u2192 T in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.31 \"Germline mutations of the CDKN2 gene in UK melanoma families.\" Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N.K., Frischauf A.-M., Bataille V., Peters G., Cuzick J., Selby P., Bishop D.T., Bishop J.N. Hum. Mol. Genet. 6:2061-2067(1997) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-24; ILE-53 AND THR-118, VARIANT THR-148.",
            "G \u2192 R in CMM2. 1 Publication Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.37 \"Germline mutation of ARF in a melanoma kindred.\" Hewitt C., Lee Wu C., Evans G., Howell A., Elles R.G., Jordan R., Sloan P., Read A.P., Thakker N. Hum. Mol. Genet. 11:1273-1279(2002) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CMM2 ARG-122.",
            "V \u2192 D in CMM2; impairs the function. 3 Publications Manually curated information for which there is published experimental evidence. More\u2026 Manual assertion based on experiment ini Ref.24 \"Germline p16 mutations in familial melanoma.\" Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A.T., Ally D.S., Sheahan M.D., Clark W.H. Jr., Tucker M.A., Dracopoli N.C. Nat. Genet. 8:15-21(1994) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS CMM2 PRO-87; TRP-101 AND ASP-126, VARIANTS THR-49; SER-71 AND THR-148. Ref.28 \"Mutations associated with familial melanoma impair p16INK4 function.\" Ranade K., Hussussian C.J., Sikorski R.S., Varmus H.E., Goldstein A.M., Tucker M.A., Serrano M., Hannon G.J., Beach D., Dracopoli N.C. Nat. Genet. 10:114-116(1995) [PubMed] [Europe PMC] [Abstract] Cited for: CHARACTERIZATION OF VARIANTS THR-49; SER-71; LEU-81; PRO-87; TRP-101; ASP-126 AND THR-148. Ref.35 \"A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.\" Goldstein A.M., Liu L., Shennan M.G., Hogg D., Tucker M.A., Struewing J.P. Br. J. Cancer 85:527-530(2001) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT CMM2 ASP-126."
        ],
        [
            "Graphical view",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            ""
        ],
        [
            "Feature identifier",
            "VAR_058549",
            "VAR_001413",
            "VAR_001414",
            "VAR_001416",
            "VAR_001418",
            "VAR_001419",
            "VAR_058551",
            "VAR_001420",
            "VAR_001423",
            "VAR_001424",
            "VAR_001427",
            "VAR_001430",
            "VAR_058553",
            "VAR_001432",
            "VAR_001437",
            "VAR_058555",
            "VAR_058556",
            "VAR_058557",
            "VAR_058558",
            "VAR_001449",
            "VAR_001451",
            "VAR_012317",
            "VAR_001453",
            "VAR_001454",
            "VAR_023604",
            "VAR_001457",
            "VAR_001458",
            "VAR_001459",
            "VAR_001460",
            "VAR_001462",
            "VAR_001464",
            "VAR_001466",
            "VAR_035068",
            "VAR_001471",
            "VAR_001472",
            "VAR_035069",
            "VAR_001479"
        ],
        [
            "Actions",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            "",
            ""
        ]
    ],
    "pageTitle": "CDKN2A - Cyclin-dependent kinase inhibitor 2A - Homo sapiens (Human)",
    "title": "",
    "url": "http://www.uniprot.org/uniprot/P42771",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988061.16/warc/CC-MAIN-20150728002308-00237-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 799818351,
    "recordOffset": 799736394,
    "tableOrientation": "HORIZONTAL",
    "lastModified": "Wed, 22 Jul 2015 00:00:00 GMT",
    "textBeforeTable": "See also OMIM:155601 Disease descriptionA malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. Disease susceptibility is associated with variations affecting the gene represented in this entry. VARIANTS CMM2 THR-ALA-19 INS; VAL-35; ARG-67; 67-GLY--ASN-71 DEL; TYR-74; PRO-77; PRO-80; THR-81 AND ARG-97, VARIANTS GLN-24; GLY-69 AND SER-114, CHARACTERIZATION OF VARIANTS. Cited for: Abstract] Europe PMC] [ PubMed] [ Hum. Mutat. 30:564-574(2009) [ Bressac-de Paillerets B. Peters G., Sarasin A., Lenoir G.M., Chompret A., Avril M.F., Mauffret O., Barrois M., Bombled J., Pham D., del Arroyo A.G., Brookes S., Kannengiesser C., \"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.\" Ref.41 VARIANT CMM2 GLN-94. Cited for: Abstract] Europe PMC] [ PubMed] [ Melanoma Res. 13:567-570(2003) [ Battelino T. Krzisnik C., Trebusak-Podkrajsek K., Hocevar M., Avbelj M., \"A novel L94Q mutation in the CDKN2A gene",
    "textAfterTable": "Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) The disease is caused by mutations affecting the gene represented in this entry. Disease descriptionAn inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer. See also OMIM:606719 Feature key Position(s) Length Description Graphical view Feature identifier Actions <p>Describes natural variant(s) of the protein sequence.</p><p><a href='../manual/variant' target='_top'>More...</a></p>Natural varianti 101\u00a0\u2013\u00a0101 1 G \u2192 W in CMM2 and FAMMMPC; impairs the function. 3 Publications <p>Manually curated information for which there is published experimental evidence.</p> <p><a href=\"/manual/evidences#ECO:0000269\">More\u2026</a></p> Manual assertion based on experiment ini Ref.24 \"Germline p16 mutations in familial melanoma.\" Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A.T., Ally D.S., Sheahan M.D., Clark W.H. Jr., Tucker M.A., Dracopoli N.C. Nat. Genet. 8:15-21(1994) [ PubMed] [ Europe PMC] [ Abstract]",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}